Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2022

May 17, 2022

SELL
$2.85 - $3.73 $456,000 - $596,800
-160,000 Reduced 31.27%
351,700 $1.16 Million
Q4 2021

Feb 15, 2022

BUY
$3.24 - $5.18 $51,192 - $81,844
15,800 Added 3.19%
511,700 $1.72 Million
Q3 2021

Nov 16, 2021

BUY
$3.94 - $5.84 $771,452 - $1.14 Million
195,800 Added 65.24%
495,900 $2.53 Million
Q2 2021

Aug 16, 2021

SELL
$4.26 - $6.5 $1.2 Million - $1.83 Million
-281,400 Reduced 48.39%
300,100 $1.31 Million
Q1 2021

May 18, 2021

SELL
$5.03 - $8.8 $708,727 - $1.24 Million
-140,900 Reduced 19.5%
581,500 $3.61 Million
Q4 2020

Feb 17, 2021

BUY
$4.04 - $5.31 $457,732 - $601,623
113,300 Added 18.6%
722,400 $3.53 Million
Q3 2020

Nov 17, 2020

SELL
$3.64 - $7.76 $4.67 Million - $9.96 Million
-1,283,000 Reduced 67.81%
609,100 $2.56 Million
Q2 2020

Aug 17, 2020

BUY
$4.78 - $8.26 $4.28 Million - $7.39 Million
894,600 Added 89.68%
1,892,100 $13.1 Million
Q1 2020

May 15, 2020

SELL
$4.0 - $21.53 $227,200 - $1.22 Million
-56,800 Reduced 5.39%
997,500 $3.99 Million
Q4 2019

Feb 14, 2020

BUY
$13.94 - $24.12 $12 Million - $20.8 Million
861,900 Added 447.97%
1,054,300 $22.6 Million
Q3 2019

Nov 14, 2019

BUY
$13.89 - $23.16 $445,869 - $743,436
32,100 Added 20.02%
192,400 $2.92 Million
Q2 2019

Aug 15, 2019

BUY
$16.27 - $20.51 $359,567 - $453,271
22,100 Added 15.99%
160,300 $3.11 Million
Q1 2019

May 16, 2019

SELL
$12.61 - $22.33 $2.35 Million - $4.15 Million
-186,000 Reduced 57.37%
138,200 $2.87 Million
Q4 2018

Feb 15, 2019

SELL
$12.41 - $22.98 $2.21 Million - $4.1 Million
-178,200 Reduced 35.47%
324,200 $4.41 Million
Q3 2018

Nov 14, 2018

BUY
$2.45 - $16.27 $1.23 Million - $8.17 Million
502,400 New
502,400 $8.17 Million

Others Institutions Holding AMRN

About AMARIN CORP PLCUK


  • Ticker AMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 403,206,016
  • Market Cap $202M
  • Description
  • Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...
More about AMRN
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.